SPA
IART icon

Sherbrooke Park Advisers’s Integra LifeSciences IART Stock Holding History

Sherbrooke Park Advisers’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,512
Closed -$227K – 557
2023
Q2 		$227K Sell
5,512
-2,482
-31% -$119K 0.12% 285
2023
Q1 		$459K Buy
+7,994
New +$450K 0.69% 35

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sherbrooke Park Advisers's IART Position: Q3 2023 in Review

Sherbrooke Park Advisers sold out of Integra LifeSciences (IART) in Q3 2023, closing a stake of 5,512 shares — an estimated $227K sold.

Sherbrooke Park Advisers first reported a position in IART in Q1 2023 and held it in 2 quarters. The position peaked at $459K in Q1 2023. 262 funds tracked by Wall St. Rank hold IART as of Q3 2023.

  • Sherbrooke Park Advisers reported no remaining Integra LifeSciences position as of Q3 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 5,512 Integra LifeSciences shares in Q3 2023, an estimated $227K.
  • Sherbrooke Park Advisers first reported a position in Integra LifeSciences in Q1 2023 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Integra LifeSciences position peaked at $459K in Q1 2023.
  • 262 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.